PRINSTON ANNOUNCES APPROVAL OF GENERIC DIOVAN-HCT® TABLETS FROM THE U.S. FOOD AND DRUG ADMINISTRATION
CRANBURY, NJ – November 5, 2014 – Prinston Pharmaceutical, Inc. is proud to announce that the U.S. Food and Drug Administration (FDA) have approved its generic equivalent of Zestril® (Lisinopril Tablets USP), 2.5mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg. Prinston will be launching Lisinopril in January 2015 via its generic division, Solco Healthcare, LLC.
"Prinston acquired the ANDA for Lisinopril earlier this year and now bringing it to the market after successfully transferring it to our manufacturing facility located in Linhai, China", said Jun Du, President and Chief Executive Officer of Prinston.
According to IMS Health (NSP), U.S. brand and generic sales of lisinopril tablets products were approximately $159.4 million for the 12 months ending in October 2014.
About Prinston Pharmaceutical, Inc. Prinston Pharmaceutical, Inc. is a fast growing, emerging global pharmaceutical company, located in Cranbury, New Jersey, USA. We are a fully integrated pharmaceutical company engaged in product development, product registration, manufacturing, marketing and sales of high quality affordable generic prescription products to our customers. Our highly experienced R&D team meets market needs through innovation, rapidly bringing high quality products to the US market, to help patients get the best pharmaceutical products at an affordable cost. We deliver and maintain the highest quality standard and integrity in all of our products, which are manufactured by the company or its partners around the world in world-class cGMP (current Good Manufacturing Practices) manufacturing facilities.Tweet